Drug reps today are facing an increasingly strong imperative to depart from traditional promotional activities simply aimed at getting doctors’ prescriptions. For these reps to shift to communications focusing on proper drug use, the key will be their performance reviews.…
HOME > REGULATORY
REGULATORY
- Japan Hammers Out New 5-Year Health, Medical Strategy
March 30, 2020
- New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
- PMDA Asking Companies to Seek Advice for Trial Rescheduling
March 30, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Ex-Tokyo Tech President Yoshinao Mishima Named AMED Chief from April
March 30, 2020
- Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate
March 27, 2020
- ICH Vancouver Meeting Cancelled due to COVID-19 Pandemic
March 27, 2020
- MHLW to Make Pediatric Medical Database Available to Researchers on Trial Basis
March 26, 2020
- OxyContin’s Chronic Pain Nod Delayed as Distribution System Not Ready
March 26, 2020
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
- MHLW Pharma Bureau Chief Tarumi Tapped to Lead Coronavirus Reponses, Mitsuaki Kamata to Take Over
March 25, 2020
- Drug Pricing Rules to Be Applied to Zolgensma: Chuikyo
March 25, 2020
- Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
- Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
- Japan’s First Ophthalmology Regenerative Medicine Product Approved: J-TEC
March 23, 2020
- Japan Eases 30-Day Inspection Rules to Expedite Coronavirus Trials
March 23, 2020
- MHLW Issues COVID-19 Treatment Guide
March 19, 2020
- Increase Copay for OTC-Like Drugs under New Mixed-Care Scheme: Professor
March 19, 2020
- 3 Key Antibiotics to Receive Price Raises through Unprofitability Re-Pricing
March 18, 2020
- Japan Grants Orphan Status to 7 Drugs
March 18, 2020
ページ
Eisai is aiming to notch up a compound annual growth rate (CAGR) of 20% over FY2020-2025 under its five-year business plan. The primary driver will certainly be Lenvima (lenvatinib), a fast-growing cancer drug that has earned an up-to-US$5.76 billion alliance…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Look into the heart of every successful company, the businesses that have made a real impact on the world, and you’ll notice they all share a common trait.The people. But not just any people, as Jim Collins famously said…“People are…